SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Interpace Biosciences (IDXG) Q3 Revenue Rose 18% to $10.4M

Q3 2026 revenue rose 18% year over year to $10.4M; Adjusted EBITDA was $2.1M versus $1.3M a year earlier. Loss from continuing operations was $1.5M, including approximately $4.1M in non-recurring stock compensation and legal expenses.Material DetailsContext by AI AnalystThis is an early comparable…

IDXG

Related stories